Foghorn Therapeutics Inc.
FHTX
$4.48
-$0.10-2.18%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -1.99% | 16.78% | 8.14% | -3.77% | -68.04% |
Total Depreciation and Amortization | 3.82% | -7.33% | -5.27% | -2.00% | -1.39% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -10.54% | -58.52% | 54.34% | 3.49% | -17.12% |
Change in Net Operating Assets | -55.12% | 45.82% | -4.40% | -12.32% | 55.46% |
Cash from Operations | -16.73% | 17.75% | 12.98% | -6.55% | -1.22% |
Capital Expenditure | -55.02% | -1,717.65% | 83.17% | -172.97% | 54.88% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -200.00% |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 137.32% | -239.71% | -166.03% | -27.33% | -2.82% |
Cash from Investing | 136.35% | -241.11% | -166.34% | -27.52% | -2.71% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -99.72% | -98.61% | 8,760.41% | 527.42% | -86.59% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 100.00% | -100.00% | -- | -- | -- |
Cash from Financing | -99.62% | -98.98% | 8,743.70% | 527.42% | -86.59% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 97.26% | -236.14% | 5,611.91% | -110.80% | -20.42% |